19 November 2026
by Jeff Craven

Recon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-T

Recon-RF-Dept-380x215.png

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US

  • FDA approves Regeneron's drug for generalized myasthenia gravis (Reuters) (The Pharma Letter)
  • Sanofi's pill becomes first US-approved drug for rare neurological disorder (Reuters) (The Pharma Letter)
  • FDA approves GSK's second lung cancer drug from historic Nuvalent deal (Reuters) (Endpoints)
  • After four biotech owners and a major trial failure, Beren's rare pediatric disease drug finally wins approval (Endpoints)
  • White House pulls FDA nominee Overton amid uncertain Senate support (Endpoints) (STAT)
  • AstraZeneca’s sonesitatug vedotin BLA accepted for priority review (The Pharma Letter)
  • Simpler phase 1 protocols, earlier FDA engagement could cut first-in-human trial delays (Pink Sheet)
  • FDA aims to speed reviews abroad by letting sponsors share approval packages (Pink Sheet)
  • Wilserdly approval lifts FDA’s 2026 novel agent count past 2025 total (Pink Sheet)
  • National Drug Code update: ‘Start planning now’ for 2033 deadline, FDA says (Pink Sheet)

In Focus: International

  • Denmark compensates patients for vision loss linked to Novo Nordisk drugs (Reuters)
  • TGA takes strong action to protect Australians from unlawful therapeutic goods (The Pharma Letter)
  • MHRA plans more systematic reviews of sex-specific drug evidence (Pink Sheet)
  • China basic medical insurance covers CAR-T for first time (Pink Sheet)
  • Japan reimburses Leqembi SC, but Kisunla price to be cut (Pink Sheet)
  • EMA targets weak links in biomarker-guided drug development (Pink Sheet)
  • Should EU JCAs mean AMNOG reform in Germany? (Pink Sheet)
  • EMA aligns with US and Canada in easing nitrosamine impurities limits (Pink Sheet)
  • HK-listed Guangzhou Innogen signs over $1 billion licensing deal for diabetes drug (Reuters)
  • Pharmacy chain Big Caring ends 0.9% higher after $155 million Malaysia IPO (Reuters)

Pharma & Biotech

  • Sanofi weighs takeover of US drugmaker Insmed (Reuters)
  • Pfizer gets into in vivo CAR-T with up to $2.6B Chinese biotech licensing deal (Endpoints) (BioPharma Dive)
  • Merck axes $2.7B BTK inhibitor program after seeing phase 3 data (Fierce Biotech) (Endpoints)
  • AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets (Endpoints) (Reuters)
  • nChroma halts its only clinical trial, lays off half its staff in latest genetic medicine setback (Endpoints)
  • Lilly’s dopamine drug mevidalen fails phase 2 study in Alzheimer’s (Endpoints)
  • Biogen says low dose of its experimental tau-reducing drug fares even better after nearly two years (Endpoints)
  • Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows (Reuters)
  • Merck, Isomorphic Labs partner to develop oncology drug candidates (STAT)
  • Clene Nanomedicine uses CRO Veristat’s biostatistics platform for FDA submission (Fierce Biotech)

Medtech

  • Medtronic wins FDA general surgery clearance for Hugo, expanding challenge to Da Vinci (Medtech Insight) (MedTech Dive)
  • Science Corporation raises $400M to commercialize BCI device (MedTech Dive)
  • Hone Health raises $228M in equity and growth funding, backed by General Catalyst, celeb investors (Medtech Insight)
  • Galvanize raises $130M to advance pulsed electric field ablation (MedTech Dive)
  • Why FDA’s home-ventilator product code undercounts a thinning market (Medtech Insight)
  • Jefferies Healthcare Conference: Globus targets Nevro right-sizing and outcomes improvements (Medtech Insight)
  • Wearable data glut meets proof and payment gaps, Milken panelists say (Medtech Insight)
  • HLTH 2026: NuraLogix introduces new compact smart mirror to predict health risks (Medtech Insight)
  • Medtronic’s Contego deal demonstrates fruits of staged M&A strategy (Medtech Insight)
  • Senseonics, Beta Bionics integrate diabetes technology (MedTech Dive)

Food & Nutrition

  • Senators ask HHS Inspector General to investigate Cyclospora outbreak response (Food Safety News)
  • EU too slow tackling health risks from 'forever chemicals', auditors say (Reuters)
  • FDA report on romaine outbreak has much information redacted (Food Safety News)

Government & Legal

  • Influential preventive services panel to meet for first time in more than a year (STAT)
  • Medicare for All to control drug prices? Time to ‘calm down a little,’ Senator says (Pink Sheet)
  • Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’ (STAT)
  • Rare diseases can’t wait for perfect data – The case for adequately documented natural history evidence for historical controls (FDA Law Blog)

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.